Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 45.06 Million USD | -5.54% |
| 2022 | 47.71 Million USD | 597.22% |
| 2021 | 6.84 Million USD | 34.76% |
| 2020 | 5.07 Million USD | -15.73% |
| 2019 | 6.02 Million USD | -0.83% |
| 2018 | 6.07 Million USD | 30.23% |
| 2017 | 4.66 Million USD | 3.22% |
| 2016 | 4.52 Million USD | -2.02% |
| 2015 | 4.61 Million USD | -51.39% |
| 2014 | 9.49 Million USD | 29.57% |
| 2013 | 7.32 Million USD | 57.76% |
| 2012 | 4.64 Million USD | 5396.26% |
| 2011 | 84.47 Thousand USD | -10.86% |
| 2010 | 94.76 Thousand USD | -3.7% |
| 2009 | 98.41 Thousand USD | 29.19% |
| 2008 | 76.17 Thousand USD | 92.19% |
| 2007 | 39.63 Thousand USD | 110.05% |
| 2006 | 18.87 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 44.49 Million USD | -1.27% |
| 2024 Q2 | 46.02 Million USD | 3.44% |
| 2023 Q1 | 44.81 Million USD | -6.06% |
| 2023 FY | 45.06 Million USD | -5.54% |
| 2023 Q2 | 45.97 Million USD | 2.58% |
| 2023 Q3 | 45.36 Million USD | -1.33% |
| 2023 Q4 | 45.06 Million USD | -0.65% |
| 2022 Q3 | 45.56 Million USD | 4.45% |
| 2022 FY | 47.71 Million USD | 597.22% |
| 2022 Q2 | 43.61 Million USD | 661.9% |
| 2022 Q4 | 47.71 Million USD | 4.72% |
| 2022 Q1 | 5.72 Million USD | -16.34% |
| 2021 Q4 | 6.84 Million USD | 63.16% |
| 2021 Q3 | 4.19 Million USD | 6.04% |
| 2021 Q2 | 3.95 Million USD | -9.31% |
| 2021 Q1 | 4.36 Million USD | -14.12% |
| 2021 FY | 6.84 Million USD | 34.76% |
| 2020 FY | 5.07 Million USD | -15.73% |
| 2020 Q1 | 5.34 Million USD | -11.32% |
| 2020 Q3 | 5.1 Million USD | -1.62% |
| 2020 Q4 | 5.07 Million USD | -0.43% |
| 2020 Q2 | 5.18 Million USD | -2.99% |
| 2019 Q2 | 6.11 Million USD | -11.23% |
| 2019 Q3 | 6.38 Million USD | 4.31% |
| 2019 Q4 | 6.02 Million USD | -5.58% |
| 2019 FY | 6.02 Million USD | -0.83% |
| 2019 Q1 | 6.89 Million USD | 13.42% |
| 2018 FY | 6.07 Million USD | 30.23% |
| 2018 Q4 | 6.07 Million USD | 47.41% |
| 2018 Q3 | 4.12 Million USD | -21.72% |
| 2018 Q2 | 5.26 Million USD | -17.63% |
| 2018 Q1 | 6.39 Million USD | 37.02% |
| 2017 Q2 | 4.1 Million USD | -23.54% |
| 2017 FY | 4.66 Million USD | 3.22% |
| 2017 Q4 | 4.66 Million USD | 32.21% |
| 2017 Q3 | 3.52 Million USD | -14.04% |
| 2017 Q1 | 5.36 Million USD | 18.79% |
| 2016 Q1 | 3.28 Million USD | -28.78% |
| 2016 Q3 | 3.02 Million USD | 21.67% |
| 2016 Q2 | 2.48 Million USD | -24.27% |
| 2016 Q4 | 4.52 Million USD | 49.3% |
| 2016 FY | 4.52 Million USD | -2.02% |
| 2015 Q4 | 4.61 Million USD | 114.06% |
| 2015 Q2 | 3.05 Million USD | -15.5% |
| 2015 Q1 | 3.61 Million USD | -61.96% |
| 2015 Q3 | 2.15 Million USD | -29.36% |
| 2015 FY | 4.61 Million USD | -51.39% |
| 2014 Q2 | 11.11 Million USD | -44.5% |
| 2014 Q4 | 9.49 Million USD | -7.19% |
| 2014 Q3 | 10.22 Million USD | -8.01% |
| 2014 FY | 9.49 Million USD | 29.57% |
| 2014 Q1 | 20.02 Million USD | 173.41% |
| 2013 FY | 7.32 Million USD | 57.76% |
| 2013 Q4 | 7.32 Million USD | 112.59% |
| 2013 Q3 | 3.44 Million USD | -9.79% |
| 2013 Q2 | 3.81 Million USD | 36.12% |
| 2013 Q1 | 2.8 Million USD | -39.56% |
| 2012 FY | 4.64 Million USD | 5396.26% |
| 2012 Q3 | 103.99 Thousand USD | 3.56% |
| 2012 Q2 | 100.41 Thousand USD | 6.71% |
| 2012 Q1 | 94.1 Thousand USD | 11.4% |
| 2012 Q4 | 4.64 Million USD | 4364.9% |
| 2011 FY | 84.47 Thousand USD | -10.86% |
| 2011 Q4 | 84.47 Thousand USD | 3.23% |
| 2011 Q3 | 81.83 Thousand USD | 4.49% |
| 2011 Q2 | 78.31 Thousand USD | -20.71% |
| 2011 Q1 | 98.77 Thousand USD | 4.23% |
| 2010 Q1 | 105.78 Thousand USD | 7.49% |
| 2010 FY | 94.76 Thousand USD | -3.7% |
| 2010 Q2 | 111.48 Thousand USD | 5.38% |
| 2010 Q3 | 86.24 Thousand USD | -22.64% |
| 2010 Q4 | 94.76 Thousand USD | 9.88% |
| 2009 Q1 | 81.46 Thousand USD | 6.94% |
| 2009 Q4 | 98.41 Thousand USD | 10.65% |
| 2009 Q3 | 88.94 Thousand USD | 4.49% |
| 2009 Q2 | 85.11 Thousand USD | 4.48% |
| 2009 FY | 98.41 Thousand USD | 29.19% |
| 2008 Q4 | 76.17 Thousand USD | 11.06% |
| 2008 Q2 | 65.28 Thousand USD | 16.92% |
| 2008 Q3 | 68.59 Thousand USD | 5.06% |
| 2008 FY | 76.17 Thousand USD | 92.19% |
| 2008 Q1 | 55.83 Thousand USD | 40.87% |
| 2007 Q3 | 34.99 Thousand USD | 54.32% |
| 2007 FY | 39.63 Thousand USD | 110.05% |
| 2007 Q2 | 22.68 Thousand USD | 20.19% |
| 2007 Q1 | 18.87 Thousand USD | 0.0% |
| 2007 Q4 | 39.63 Thousand USD | 13.25% |
| 2006 Q4 | 18.87 Thousand USD | 0.0% |
| 2006 FY | 18.87 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -392.686% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1796.717% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 68.27% |
| Azitra, Inc. | 2.2 Million USD | -1946.278% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -1103.043% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -588.983% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | -146.883% |
| CEL-SCI Corporation | 17.31 Million USD | -160.296% |
| iBio, Inc. | 7.41 Million USD | -508.178% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | -15.566% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -535.687% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 2.732% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -260.098% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -687.867% |
| NanoViricides, Inc. | 1.35 Million USD | -3216.661% |
| Oragenics, Inc. | 1.79 Million USD | -2406.199% |
| BiomX Inc. | 55.07 Million USD | 18.173% |
| BiomX Inc. | 55.07 Million USD | 18.173% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 11.401% |
| Palatin Technologies, Inc. | 10.85 Million USD | -315.211% |
| Scorpius Holdings, Inc. | 22.74 Million USD | -98.151% |